Compare Sana Biotechnology Inc (SANA) vs Financial Select Sector SPDR Fund (XLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Financial Select Sector SPDR Fund — how do they compare? Sana Biotechnology Inc trades at $2.79 (market cap $836.71M), while Financial Select Sector SPDR Fund trades at $54.73 (market cap $50.06B). The key difference: Financial Select Sector SPDR Fund is far larger — about 59.8× Sana Biotechnology Inc's market cap, and Financial Select Sector SPDR Fund is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 23 Days and Financial Select Sector SPDR Fund for 104 Days on average.
| SANA | XLF | |
|---|---|---|
Market Cap | $836.71M | $50.06B |
Volume | 4,507,444 | 47,464,120 |
Sector | Health | — |
52-Week High | $5.92 | $58.55 |
52-Week Low | $2.68 | $47.80 |
Typical Hold Time | 23 Days | 104 Days |
Enterprise Value | $749.96M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent news highlights multiple investor conference presentations and ongoing legal scrutiny regarding fiduciary duties.
Despite strong analyst support (82% buy ratings), SANA's lack of revenue generation and negative profitability metrics present substantial investment risk. The company's cash flow remains negative, requiring continued financing. Near-term catalysts include upcoming Q3 earnings and clinical developments, but investors should weigh the high-risk profile against potential long-term biotechnology breakthroughs.
XLF trades at $54.23, up 0.89% on the day, while technical indicators show a bearish bias with moving averages signaling caution. The ETF faces sector headwinds as financial stocks lag the S&P 500 by the widest margin since 1990 despite rising bank profits. Recent Fed stress test changes and interest rate hikes create both opportunities and challenges for financial sector performance.
Financial sector exposure through XLF offers potential upside from rising interest rates, though regulatory uncertainty and market underperformance present near-term risks. The ETF's focus on large-cap financial firms provides stability, but sector rotation trends and political volatility could impact medium-term returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Financial Select Sector SPDR Fund
The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.
Read more on XLF →
